This page has only limited features, please log in for full access.

Unclaimed
Bing-Juin Chiang
Division of Urology, Department of Surgery, Cardinal Tien Hospital and School of Medicine, Fu-Jen Catholic University, New Taipei City 23148, Taiwan

Basic Info

Basic Info is private.

Honors and Awards

The user has no records in this section


Career Timeline

The user has no records in this section.


Short Biography

The user biography is not available.
Following
Followers
Co Authors
The list of users this user is following is empty.
Following: 0 users

Feed

Journal article
Published: 05 August 2021 in Cancers
Reads 0
Downloads 0

To assess the predictive value of tumor burden on the biochemical response, and radiological response in Taiwanese metastatic castration-resistant prostate cancer (mCRPC) patients receiving enzalutamide. The mCRPC patients treated with enzalutamide were recruited from three hospitals. High tumor burden (HTB) was classified as metastases at either appendicular bone or visceral organ. Good prostate-specific antigen (PSA) response was defined as PSA reduction of 80%. In this cohort, there were 104 (54.2%) HTB patients and 88 (45.8%) with low tumor burden (LTB). Compared to LTB patients, fewer HTB patients had good PSA response (odds ratio: 0.43, range: 0.22–0.87, p = 0.019) and fewer radiological response (complete and partial remission) (odds ratio: 0.78, range: 0.36–1.68, p = 0.52) to enzalutamide. The disease control rate which also contained stable disease, was still lower in HTB (76.0%) than LTB group (92.9%, OR: 0.24, range: 0.07–0.77, p = 0.016) in the multivariable model. In addition, HTB patients had significantly shorter progression–free survival duration than did LTB patients (median: 8.3 vs. 21.6 months, log-rank test p = 0.003) in the univariable analysis. The tumor burden before the use of enzalutamide was associated with treatment outcomes. HTB reduced PSA response rate, radiological response rate and progression-free survival duration.

ACS Style

Yu-Ting Hsieh; Bing-Juin Chiang; Chia-Chang Wu; Chun-Hou Liao; Chia-Da Lin; Chung-Hsin Chen. High Tumor Burden Predicts Poor Response to Enzalutamide in Metastatic Castration-Resistant Prostate Cancer Patients. Cancers 2021, 13, 3966 .

AMA Style

Yu-Ting Hsieh, Bing-Juin Chiang, Chia-Chang Wu, Chun-Hou Liao, Chia-Da Lin, Chung-Hsin Chen. High Tumor Burden Predicts Poor Response to Enzalutamide in Metastatic Castration-Resistant Prostate Cancer Patients. Cancers. 2021; 13 (16):3966.

Chicago/Turabian Style

Yu-Ting Hsieh; Bing-Juin Chiang; Chia-Chang Wu; Chun-Hou Liao; Chia-Da Lin; Chung-Hsin Chen. 2021. "High Tumor Burden Predicts Poor Response to Enzalutamide in Metastatic Castration-Resistant Prostate Cancer Patients." Cancers 13, no. 16: 3966.

Journal article
Published: 29 June 2021 in International Journal of Molecular Sciences
Reads 0
Downloads 0

(1) Background: We established a new bladder ischemia rat model through bilateral partial iliac arterial occlusion (BPAO) and investigated the therapeutic effect of adipose-derived stem cells (ADSCs) and ADSC-derived microvesicles (MVs); (2) Methods: The study included four groups: (1) sham, (2) BPAO, (3) BPAO + ADSCs, and (4) BPAO + ADSC-derived MVs. Female Wistar rats with BPAO were injected with ADSCs or ADSC-derived MVs through the femoral artery. Doppler flowmetry and real-time laser speckle contrast imaging were performed to quantify blood flow in the common iliac arteries and bladder microcirculation. A 24-h behavior study and transcystometrogram were conducted after 2 weeks. Bladder histology, immunostaining, and lipid peroxidation assay were performed. The expressions of P2X2, P2X3, M2, and M3 receptors and nerve growth factor (NGF) were evaluated; (3) Results: BPAO significantly reduced bladder microcirculation, intercontraction interval (ICI), and bladder volume and increased the amplitude of nonvoiding contraction, neutrophil infiltration, and malondialdehyde and NGF levels. ADSCs and ADSC-derived MVs significantly ameliorated these effects. The results of Western blot showed that the BPAO group exhibited the highest expression of M3 and P2X2 receptors. ADSCs significantly attenuated the expressions of M2 and P2X2 receptors. ADSC-derived MVs significantly attenuated the expressions of M3 and P2X2 receptors; (4) Conclusions: ADSCs and ADSC-derived MVs ameliorated the adverse effects of BPAO including bladder overactivity, bladder ischemia, and oxidative stress. Inflammation, muscarinic signaling, purinergic signaling, and NGF might be involved in the therapeutic mechanism.

ACS Style

Bing-Juin Chiang; Chun-Hou Liao; Su-Han Mao; Chiang-Ting Chien. Adipose-Derived Stem Cells and Their Derived Microvesicles Ameliorate Detrusor Overactivity Secondary to Bilateral Partial Iliac Arterial Occlusion-Induced Bladder Ischemia. International Journal of Molecular Sciences 2021, 22, 7000 .

AMA Style

Bing-Juin Chiang, Chun-Hou Liao, Su-Han Mao, Chiang-Ting Chien. Adipose-Derived Stem Cells and Their Derived Microvesicles Ameliorate Detrusor Overactivity Secondary to Bilateral Partial Iliac Arterial Occlusion-Induced Bladder Ischemia. International Journal of Molecular Sciences. 2021; 22 (13):7000.

Chicago/Turabian Style

Bing-Juin Chiang; Chun-Hou Liao; Su-Han Mao; Chiang-Ting Chien. 2021. "Adipose-Derived Stem Cells and Their Derived Microvesicles Ameliorate Detrusor Overactivity Secondary to Bilateral Partial Iliac Arterial Occlusion-Induced Bladder Ischemia." International Journal of Molecular Sciences 22, no. 13: 7000.

Journal article
Published: 27 November 2020 in Journal of Clinical Medicine
Reads 0
Downloads 0

We sought to examine the effect of tumor location on the prognosis of patients with upper tract urothelial carcinoma (UTUC) treated with radical nephroureterectomy (RNU). This retrospective study came from the Taiwan UTUC Collaboration Group, which consisted of 2658 patients at 15 institutions in Taiwan from 1988 to 2019. Patients with kidney-sparing management, both renal pelvic and ureteral tumors, as well as patients lacking complete data were excluded; the remaining 1436 patients were divided into two groups: renal pelvic tumor (RPT) and ureteral tumor (UT), with 842 and 594 patients, respectively. RPT was associated with more aggressive pathological features, including higher pathological T stage (p < 0.001) and the presence of lymphovascular invasion (p = 0.002), whereas patients with UT often had synchronous bladder tumor (p < 0.001), and were more likely to bear multiple lesions (p = 0.001). Our multivariate analysis revealed that UT was a worse prognostic factor compared with RPT (overall survival: HR 1.408, 95% CI 1.121–1.767, p = 0.003; cancer-specific survival: HR 1.562, 95% CI 1.169–2.085, p = 0.003; disease-free survival: HR 1.363, 95% CI 1.095–1.697, p = 0.006; bladder-recurrence-free survival: HR 1.411, 95% CI 1.141–1.747, p = 0.002, respectively). Based on our findings, UT appeared to be more malignant and had a worse prognosis than RPT.

ACS Style

Lian-Ching Yu; Chao-Hsiang Chang; Chi-Ping Huang; Chao-Yuan Huang; Jian-Hua Hong; Ta-Yao Tai; Han-Yu Weng; Chi-Wen Lo; Chung-You Tsai; Yu-Khun Lee; Yao-Chou Tsai; Thomas Y. Hsueh; Yung-Tai Chen; I-Hsuan Chen; Bing-Juin Chiang; Jen-Shu Tseng; Chia-Chang Wu; Wei-Yu Lin; Tsu-Ming Chien; Zai-Lin Sheu; Ching-Chia Li; Hung-Lung Ke; Wei-Ming Li; Hsiang-Ying Lee; Wen-Jeng Wu; Hsin-Chih Yeh. Prognostic Significance of Primary Tumor Location in Upper Tract Urothelial Carcinoma Treated with Nephroureterectomy: A Retrospective, Multi-Center Cohort Study in Taiwan. Journal of Clinical Medicine 2020, 9, 3866 .

AMA Style

Lian-Ching Yu, Chao-Hsiang Chang, Chi-Ping Huang, Chao-Yuan Huang, Jian-Hua Hong, Ta-Yao Tai, Han-Yu Weng, Chi-Wen Lo, Chung-You Tsai, Yu-Khun Lee, Yao-Chou Tsai, Thomas Y. Hsueh, Yung-Tai Chen, I-Hsuan Chen, Bing-Juin Chiang, Jen-Shu Tseng, Chia-Chang Wu, Wei-Yu Lin, Tsu-Ming Chien, Zai-Lin Sheu, Ching-Chia Li, Hung-Lung Ke, Wei-Ming Li, Hsiang-Ying Lee, Wen-Jeng Wu, Hsin-Chih Yeh. Prognostic Significance of Primary Tumor Location in Upper Tract Urothelial Carcinoma Treated with Nephroureterectomy: A Retrospective, Multi-Center Cohort Study in Taiwan. Journal of Clinical Medicine. 2020; 9 (12):3866.

Chicago/Turabian Style

Lian-Ching Yu; Chao-Hsiang Chang; Chi-Ping Huang; Chao-Yuan Huang; Jian-Hua Hong; Ta-Yao Tai; Han-Yu Weng; Chi-Wen Lo; Chung-You Tsai; Yu-Khun Lee; Yao-Chou Tsai; Thomas Y. Hsueh; Yung-Tai Chen; I-Hsuan Chen; Bing-Juin Chiang; Jen-Shu Tseng; Chia-Chang Wu; Wei-Yu Lin; Tsu-Ming Chien; Zai-Lin Sheu; Ching-Chia Li; Hung-Lung Ke; Wei-Ming Li; Hsiang-Ying Lee; Wen-Jeng Wu; Hsin-Chih Yeh. 2020. "Prognostic Significance of Primary Tumor Location in Upper Tract Urothelial Carcinoma Treated with Nephroureterectomy: A Retrospective, Multi-Center Cohort Study in Taiwan." Journal of Clinical Medicine 9, no. 12: 3866.

Review
Published: 18 February 2020 in Toxins
Reads 0
Downloads 0

Intravesical botulinum toxin (BoNT) injection is effective in reducing urgency and urinary incontinence. It temporarily inhibits the detrusor muscle contraction by blocking the release of acetylcholine (Ach) from the preganglionic and postganglionic nerves in the efferent nerves. BoNT-A also blocks ATP release from purinergic efferent nerves in the detrusor muscle. In afferent nerves, BoNT-A injection markedly reduces the urothelial ATP release and increases nitric oxide (NO) release from the urothelium. BoNT-A injection in the urethra or bladder has been developed in the past few decades as the treatment method for detrusor sphincter dyssyndergia, incontinence due to neurogenic or idiopathic detrusor overactivity, sensory disorders, including bladder hypersensitivity, overactive bladder, and interstitial cystitis/chronic pelvic pain syndrome. Although the FDA only approved BoNT-A injection treatment for neurogenic detrusor overactivity and for refractory overactive bladder, emerging clinical trials have demonstrated the benefits of BoNT-A treatment in functional urological disorders. Cautious selection of patients and urodynamic evaluation for confirmation of diagnosis are crucial to maximize the successful outcomes of BoNT-A treatment.

ACS Style

Yu-Hua Lin; Bing-Juin Chiang; Chun-Hou Liao. Mechanism of Action of Botulinum Toxin A in Treatment of Functional Urological Disorders. Toxins 2020, 12, 129 .

AMA Style

Yu-Hua Lin, Bing-Juin Chiang, Chun-Hou Liao. Mechanism of Action of Botulinum Toxin A in Treatment of Functional Urological Disorders. Toxins. 2020; 12 (2):129.

Chicago/Turabian Style

Yu-Hua Lin; Bing-Juin Chiang; Chun-Hou Liao. 2020. "Mechanism of Action of Botulinum Toxin A in Treatment of Functional Urological Disorders." Toxins 12, no. 2: 129.

Review
Published: 19 September 2019 in Toxins
Reads 0
Downloads 0

Patients with benign prostatic hyperplasia (BPH) can exhibit various lower urinary tract symptoms (LUTS) owing to bladder outlet obstruction (BOO), prostatic inflammation, and bladder response to BOO. The pathogenesis of BPH involves an imbalance of internal hormones and chronic prostatic inflammation, possibly triggered by prostatic infection, autoimmune responses, neurogenic inflammation, oxidative stress, and autonomic dysfunction. Botulinum toxin A (BoNT-A) is well recognized for its ability to block acetylcholine release at the neuromuscular junction by cleaving synaptosomal-associated proteins. Although current large clinical trials have shown no clinical benefits of BoNT-A for the management of LUTS due to BPH, BoNT-A has demonstrated beneficial effects in certain subsets of BPH patients with LUTS, especially in males with concomitant chronic prostatitis/chronic pelvic pain syndrome and smaller prostate. We conducted a review of published literature in Pubmed, using Botulinum toxin, BPH, BOO, inflammation, LUTS, and prostatitis as the key words. This article reviewed the mechanisms of BPH pathogenesis and anti-inflammatory effects of BoNT-A. The results suggested that to achieve effectiveness, the treatment of BPH with BoNT-A should be tailored according to more detailed clinical information and reliable biomarkers.

ACS Style

Bing-Juin Chiang; Hann-Chorng Kuo; Chun-Hou Liao. Can Botulinum Toxin A Still Have a Role in Treatment of Lower Urinary Tract Symptoms/Benign Prostatic Hyperplasia Through Inhibition of Chronic Prostatic Inflammation? Toxins 2019, 11, 547 .

AMA Style

Bing-Juin Chiang, Hann-Chorng Kuo, Chun-Hou Liao. Can Botulinum Toxin A Still Have a Role in Treatment of Lower Urinary Tract Symptoms/Benign Prostatic Hyperplasia Through Inhibition of Chronic Prostatic Inflammation? Toxins. 2019; 11 (9):547.

Chicago/Turabian Style

Bing-Juin Chiang; Hann-Chorng Kuo; Chun-Hou Liao. 2019. "Can Botulinum Toxin A Still Have a Role in Treatment of Lower Urinary Tract Symptoms/Benign Prostatic Hyperplasia Through Inhibition of Chronic Prostatic Inflammation?" Toxins 11, no. 9: 547.

Journal article
Published: 01 March 2016 in Urological Science
Reads 0
Downloads 0

ObjectiveTo evaluate the impact of intravesical prostatic protrusion (IPP) and prostatic calcification on medical treatment for male lower urinary tract symptoms (LUTS).Materials and methodsMen over the age of 40 years with total International Prostate Symptom Score (IPSS) ≥ 8 were recruited from January to August 2013. The maximal flow rate, postvoiding residual (PVR) urine volume, total prostate volume (TPV), transitional zone volume (TZV), transitional zone index (TZI), and grades of IPP and prostate calcification were recorded. All patients received α-blocker monotherapy, and Global Response Assessment (GRA) was used to determine treatment response 1 month after the treatment. The primary end point was to compare the treatment results in patients with and without significant IPP or prostate calcification. Univariate and multivariate logistic regression analyses were performed to determine whether IPP and prostatic calcification are predictors of improved outcome (GRA ≥ 1).ResultsWe enrolled 112 men with a mean age of 65.5 (range, 42–89) years. IPP was significantly positively correlated with TPV, TZV, TZI, and PVR. Prostatic calcification was significantly negatively correlated with total IPSS, IPSS Voiding, and IPSS Storage. After 1-month treatment with α-blockers, the average total IPSS decreased from 18.2 ± 7.4 to 13.1 ± 4.5. Sixty-nine patients (61.6%) reported improved outcomes. Patients with large prostate volumes (TPV ≥ 40 mL) and small prostate volumes (TPV < 40 mL) had similar improved outcome rates (56.5% and 65.1%, respectively). Patients with significant IPP (Grades II and III) had significantly lower improved outcome rates (36.8%) than those without significant IPP (74.3%). Patients with prostatic calcification also had a significantly lower rate of improved outcome (47.9%) than those who did not (71.9%). Multivariate logistic regression analyses showed that IPP and prostatic calcification are predictors of unfavorable outcome (GRA < 1) after adjusting for age, TPV, and total IPSS.ConclusionSignificant IPP and prostatic calcification are unfavorable predictors of successful α-blocker treatment for benign prostatic hyperplasia-induced male LUTS.

ACS Style

Chia-Hao Kuei; Chun-Hou Liao; Bing-Juin Chiang; Press Enter Key For Correspondence Information. Significant intravesical prostatic protrusion and prostatic calcification predict unfavorable outcomes of medical treatment for male lower urinary tract symptoms. Urological Science 2016, 27, 13 -16.

AMA Style

Chia-Hao Kuei, Chun-Hou Liao, Bing-Juin Chiang, Press Enter Key For Correspondence Information. Significant intravesical prostatic protrusion and prostatic calcification predict unfavorable outcomes of medical treatment for male lower urinary tract symptoms. Urological Science. 2016; 27 (1):13-16.

Chicago/Turabian Style

Chia-Hao Kuei; Chun-Hou Liao; Bing-Juin Chiang; Press Enter Key For Correspondence Information. 2016. "Significant intravesical prostatic protrusion and prostatic calcification predict unfavorable outcomes of medical treatment for male lower urinary tract symptoms." Urological Science 27, no. 1: 13-16.

Journal article
Published: 01 June 2015 in Urological Science
Reads 0
Downloads 0
ACS Style

Meng-Che Chiang; Bing-Juin Chiang; Chun-Hou Liao. Bilateral adrenal tumor related to multiple endocrine neoplasia type 2. Urological Science 2015, 26, 1 .

AMA Style

Meng-Che Chiang, Bing-Juin Chiang, Chun-Hou Liao. Bilateral adrenal tumor related to multiple endocrine neoplasia type 2. Urological Science. 2015; 26 (2):1.

Chicago/Turabian Style

Meng-Che Chiang; Bing-Juin Chiang; Chun-Hou Liao. 2015. "Bilateral adrenal tumor related to multiple endocrine neoplasia type 2." Urological Science 26, no. 2: 1.

Journal article
Published: 29 July 2014 in BMC Infectious Diseases
Reads 0
Downloads 0

Emphysematous pyelonephritis (EPN) is a severe necrotizing infection of the renal parenchyma and perirenal tissues that is caused by gas-producing bacterial pathogens. Percutaneous drainage is now the gold standard of definitive management. The aim of this study is to analyze the predictors associated with failure of conservative treatment among patients with EPN and offer the recommendation of appropriate empirical antibiotic regimen. From January 2001 to December 2013, 44 consecutive patients were diagnosed with EPN. The demographic characteristics, clinical presentations, management strategies, and final outcomes were analyzed retrospectively. The overall survival rate was 88.6% (39/44). Need for emergency hemodialysis, shock on initial presentation, altered mental status, severe hypoalbuminemia, inappropriate empirical antibiotic treatment and polymicrobial infections were significantly more common in the patients who died compared with the survivors. The overall failure rate of conservative treatment was 32.6% (14/43). Severe hypoalbuminemia (p = 0.003), need for emergency hemodialysis (p = 0.03), and polymicrobial infections (p = 0.04) were significantly associated with failure of conservative treatment. Severe hypoalbuminemia was independently associated with conservative management failure (p = 0.02). Even in the patients treated with percutaneous drainage plus effective antibiotics, failure was still associated with severe hypoalbuminemia (p = 0.01). According to the in vitro susceptibility data, third-generation cephalosporins is recommended as the empirical antibiotic regimen. Both appropriate empirical antibiotic and percutaneous drainage were essential for patients with EPN. Patients with severe hypoalbuminemia had a higher risk of conservative treatment failure, and additional management may be required.

ACS Style

Yu-Chuan Lu; Bing-Juin Chiang; Yuan-Hung Pong; Kuo-How Huang; Po-Ren Hsueh; Chao-Yuan Huang; Yeong-Shiau Pu. Predictors of failure of conservative treatment among patients with emphysematous pyelonephritis. BMC Infectious Diseases 2014, 14, 1 -8.

AMA Style

Yu-Chuan Lu, Bing-Juin Chiang, Yuan-Hung Pong, Kuo-How Huang, Po-Ren Hsueh, Chao-Yuan Huang, Yeong-Shiau Pu. Predictors of failure of conservative treatment among patients with emphysematous pyelonephritis. BMC Infectious Diseases. 2014; 14 (1):1-8.

Chicago/Turabian Style

Yu-Chuan Lu; Bing-Juin Chiang; Yuan-Hung Pong; Kuo-How Huang; Po-Ren Hsueh; Chao-Yuan Huang; Yeong-Shiau Pu. 2014. "Predictors of failure of conservative treatment among patients with emphysematous pyelonephritis." BMC Infectious Diseases 14, no. 1: 1-8.